5.41
-0.13(-2.35%)
Currency In USD
| Previous Close | 5.54 |
| Open | 5.59 |
| Day High | 5.74 |
| Day Low | 5.4 |
| 52-Week High | 14.6 |
| 52-Week Low | 3.79 |
| Volume | 792,415 |
| Average Volume | 812,198 |
| Market Cap | 297.01M |
| PE | -8.2 |
| EPS | -0.66 |
| Moving Average 50 Days | 5.68 |
| Moving Average 200 Days | 6.43 |
| Change | -0.13 |
If you invested $1000 in Candel Therapeutics, Inc. (CADL) since IPO date, it would be worth $772.86 as of October 03, 2025 at a share price of $5.41. Whereas If you bought $1000 worth of Candel Therapeutics, Inc. (CADL) shares 3 years ago, it would be worth $1,690.63 as of October 03, 2025 at a share price of $5.41.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
GlobeNewswire Inc.
Sep 29, 2025 12:05 PM GMT
CAN-2409 improved disease-free survival in patients with intermediate-to-high-risk, localized prostate cancer compared to placebo in patients treated with either conventional or moderate hypofractionated radiotherapy with curative intent, independent
Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025
GlobeNewswire Inc.
Sep 17, 2025 12:05 PM GMT
NEEDHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cance
Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D., to Research Advisory Board
GlobeNewswire Inc.
Sep 02, 2025 12:05 PM GMT
NEEDHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cance